<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Varenicline tartrate - Chantix | Champix | CP 526555-18

產(chǎn)品貨號(hào)

Axon 2074 CAS [375815-87-5] MF C17H19N3O6MW 361.35 Purity: 100% Optical purity: Optically pure Soluble in water and DMSO Description Selective α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist; Smoking cessation drug. Available also another drug form, Varenicline di-HCl (Axon 1384). References Certificates Categories Extra info D.E. Jorenby et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296, 56-63. ? R.S. Obach et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos. 2006, 34, 121-30. ? K.B. Mihalak et al. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70, 801-805. Certificate of Analysis Material Safety Data Sheet CNS Pain & Inflammation nAChR Unclassified Pfizer Licensed Products Selective α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist Chemical name 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine tartrate Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [249296-44-4] Order Size Unit Price Stock 10 mg €90.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Varenicline tartrate - Chantix | Champix | CP 526555-18

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2074

CAS [375815-87-5]

MF C17H19N3O6
MW 361.35

Purity: 100%
Optical purity: Optically pure
Soluble in water and DMSO

Varenicline tartrate

Description

Selective α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist; Smoking cessation drug. Available also another drug form, Varenicline di-HCl (Axon 1384).

D.E. Jorenby et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296, 56-63.

R.S. Obach et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab. Dispos. 2006, 34, 121-30.

K.B. Mihalak et al. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70, 801-805.

Certificate of Analysis
Material Safety Data Sheet

CNS Pain & Inflammation nAChR Unclassified Pfizer Licensed Products

Selective α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist

Chemical name

7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine tartrate

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[249296-44-4]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>